| scholarly article | Q13442814 |
| P50 | author | Kian Behbakht | Q56332429 |
| P2093 | author name string | Andrew Thorburn | |
| Jacqueline Thorburn | |||
| Heide L Ford | |||
| Lianghua Bin | |||
| Christina Menke | |||
| P2860 | cites work | The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1 | Q24564859 |
| Rare loss-of-function mutation of a death receptor gene in head and neck cancer | Q28281058 | ||
| Quantitative analysis of pathways controlling extrinsic apoptosis in single cells | Q33807797 | ||
| Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. | Q33999606 | ||
| Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications | Q35781710 | ||
| NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells | Q35850681 | ||
| TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. | Q36731174 | ||
| Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway signaling. | Q36839047 | ||
| To kill a tumor cell: the potential of proapoptotic receptor agonists | Q37181734 | ||
| The TRAIL apoptotic pathway in cancer onset, progression and therapy | Q37278043 | ||
| The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling | Q37328463 | ||
| Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody | Q37367298 | ||
| Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation | Q39698787 | ||
| Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding | Q40100090 | ||
| The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells | Q40131236 | ||
| Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. | Q40149403 | ||
| Gene amplification is a mechanism of Six1 overexpression in breast cancer | Q40439862 | ||
| Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells | Q40545469 | ||
| Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. | Q40975748 | ||
| Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. | Q44165080 | ||
| The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells | Q44539646 | ||
| Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. | Q48148098 | ||
| Mutation analysis and mRNA expression of trail-receptors in human breast cancer. | Q53386106 | ||
| A matter of life and death | Q63408384 | ||
| TRAIL-R2 is not correlated with p53 status and is rarely mutated in non-small cell lung cancer | Q73505532 | ||
| Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma | Q73787515 | ||
| Extensive regions of the FADD death domain are required for binding to the TRAIL receptor DR5 | Q80346249 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1883-1892 | |
| P577 | publication date | 2011-03-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents | |
| P478 | volume | 71 |
| Q51176917 | A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance. |
| Q37299291 | Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5. |
| Q38945539 | Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism. |
| Q37003894 | Cells surviving fractional killing by TRAIL exhibit transient but sustainable resistance and inflammatory phenotypes |
| Q35327231 | Combination of TRAIL with bortezomib shifted apoptotic signaling from DR4 to DR5 death receptor by selective internalization and degradation of DR4. |
| Q35561369 | Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10. |
| Q39400148 | Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation |
| Q92756792 | Importance of TRAIL Molecular Anatomy in Receptor Oligomerization and Signaling. Implications for Cancer Therapy |
| Q38726186 | Non-cell-autonomous Effects of Autophagy Inhibition in Tumor Cells Promote Growth of Drug-resistant Cells |
| Q35853714 | On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics |
| Q36992161 | Overcoming resistance to TRAIL-induced apoptosis in solid tumor cells by simultaneously targeting death receptors, c-FLIP and IAPs |
| Q33695003 | Plasminogen activator urokinase expression reveals TRAIL responsiveness and supports fractional survival of cancer cells |
| Q36579619 | Smad7 protein induces interferon regulatory factor 1-dependent transcriptional activation of caspase 8 to restore tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis |
| Q97901404 | TRAIL of Hope Meeting Resistance in Cancer |
| Q35609438 | Targeted ovarian cancer treatment: the TRAILs of resistance. |
| Q43468001 | The plant alkaloid and anti-leukemia drug homoharringtonine sensitizes resistant human colorectal carcinoma cells to TRAIL-induced apoptosis via multiple mechanisms. |
| Q38861356 | Using natural products to promote caspase-8-dependent cancer cell death |
| Q35501202 | Verticillin A overcomes apoptosis resistance in human colon carcinoma through DNA methylation-dependent upregulation of BNIP3. |
| Q36347307 | Withanolide E sensitizes renal carcinoma cells to TRAIL-induced apoptosis by increasing cFLIP degradation |
Search more.